Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7638605B2 · kind B2 · utility
5Cited by
35References
28Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 3, 2004 |
| Grant date | Dec 29, 2009 |
| Priority date | — |
| Expiry date | Jan 21, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodes, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.